Production (Stage)
Candel Therapeutics, Inc.
CADL
$5.11
-$0.05-0.97%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -75.39% | 2,339.47% | |||
| Gross Profit | 75.39% | -2,339.47% | |||
| SG&A Expenses | 30.20% | -6.31% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.86% | -15.50% | |||
| Operating Income | -9.86% | 15.50% | |||
| Income Before Tax | 152.43% | -32.19% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 152.43% | -32.19% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 152.43% | -32.19% | |||
| EBIT | -9.86% | 15.50% | |||
| EBITDA | -10.20% | 15.94% | |||
| EPS Basic | 136.95% | -19.01% | |||
| Normalized Basic EPS | 139.01% | -12.75% | |||
| EPS Diluted | 132.85% | -19.01% | |||
| Normalized Diluted EPS | 135.94% | -12.75% | |||
| Average Basic Shares Outstanding | 41.95% | 11.09% | |||
| Average Diluted Shares Outstanding | 53.99% | 11.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||